Cbay stock forecast.

According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecastsWith stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Get the latest information on CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on liver and other chronic diseases, including its stock price, …Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Spruce Biosciences Inc have a median target of 8.50, with a high estimate of 10.00 and a low estimate of 7.00. The median ...

Nov 30, 2023 · According to 11 stock analysts, the average 12-month stock price forecast for CBAY stock stock is $20.18, which predicts an increase of 23.35%. The lowest target is $12 and the highest is $33. On average, analysts rate CBAY stock stock as a strong buy. CBAY Stock Shows Promising Performance: Analysts Predict 38.63% Increase CBAY stock had a promising performance on November 6, 2023, based on the information provided by CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...

Cymabay Therapeutics 's revenue in 2023 is $31,016,000. On average, 7 Wall Street analysts forecast CBAY's revenue for 2023 to be $3,523,442,178, with the lowest CBAY …CBAY stock has been performing well according to 12 analysts offering 12-month price forecasts. The median target price is $22.50, with a high estimate of $33.00 and a low estimate of $19.00. This indicates a potential increase of 37.95% from the last recorded price of $16.31. The consensus among 13 polled investment analysts is to buy stock in ...

Stock Price Forecast. The 23 analysts offering 12-month price forecasts for Nokia Oyj have a median target of 4.39, with a high estimate of 7.60 and a low estimate of 3.49. The median estimate ...Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40.Find real-time TNEYF - Tamarack Valley Energy Ltd stock quotes, company profile, news and forecasts from CNN Business.A high-level overview of eBay Inc. (EBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Sep 8, 2023 · Newark, California-based CymaBay Therapeutics (CBAY) was approved for uplisting to the Nasdaq in June 2014, with stock initially trading at a value of $19. Across the next 9 years they have been ...

Track Cymabay Therapeutics Inc (CBAY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...

A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary ...Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Digital Turbine Inc have a median target of 5.50, with a high estimate of 12.00 and a low estimate of 5.00. The median ...Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing.Yasmeen Rahimi's average stock forecast success ratio is 24.4% with an ... CBAY CymaBay Therapeutics ENTA Enanta Pharmaceuticals ETN Eatonplc ICPT Intercept ...That closing price of FOSL’s stock is at a discount of -300.0% from its 52-week high price of $6.08 and is indicating a discount of -3.29% from its 52-week low price of $1.57. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.37 million shares which gives us an average trading volume of 360.25K if we …Analyst Forecast According to 10 analysts, the average rating for BMEA stock is "Strong Buy." The 12-month stock price forecast is $47.7, which is an increase of 185.97% from the latest price.

CBAY one year fore… Wednesday, November 23, 2022 Edit. emporia hotels in marriott. marriott hotels in emporia va. Quality Inn Emporia November 23, 2022 Edit. Jill Scott wallpaper. ... cbay stock forecast cnn. Based on 5 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. CBAY one year …Nov 30, 2023 · According to 11 stock analysts, the average 12-month stock price forecast for CBAY stock stock is $20.18, which predicts an increase of 23.35%. The lowest target is $12 and the highest is $33. On average, analysts rate CBAY stock stock as a strong buy. Shares of CymaBay Therapeutics ( CBAY -1.16%) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday. The continued momentum is a result ...NextPlay Technologies, Inc. (NASDAQ:NXTP) announced its quarterly earnings results on Wednesday, January, 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The firm earned $4.20 million during the quarter, compared to the consensus estimate of $5.70 million.September 8, 2023 at 1:12 PM · 3 min read. Shares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it announced positive top-line results from its late ...CBAY 8.19%. 70. See CBAY Report. CymaBay Therapeutics Inc ( CBAY) is near the top in its industry group according to InvestorsObserver. CBAY gets an overall rating of 80. That means it scores higher than 80 percent of stocks. CymaBay Therapeutics Inc gets a 91 rank in the Biotechnology industry. Biotechnology is number 13 out of 148 …The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low.

CymaBay Therapeutics (CBAY) Stock Forecast & Price Target $17.90 -0.21 (-1.16%) (As of 11/22/2023 ET) Compare Share Today's Range $17.82 $18.45 50-Day …

CBAY stock performances on November 6, 2023, are expected to be positive based on the information provided. According to data from CNN Money, the 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of $22.50, with a high estimate of $33.00 and a low estimate of $19.00.Dec 1, 2023 · According to the issued ratings of 12 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Buy based on the current 11 buy ratings and 1 strong buy rating for CBAY. The average twelve-month price prediction for CymaBay Therapeutics is $22.27 with a high price target of $34.00 and a low price target of $12.00. According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecastsDiscover historical prices for CBAY stock on Yahoo Finance. View daily, weekly or monthly format back to when CymaBay Therapeutics, Inc. stock was issued.CBAY stock performances on November 6, 2023, are expected to be positive based on the information provided. According to data from CNN Money, the 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of $22.50, with a high estimate of $33.00 and a low estimate of $19.00.Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low. Nov 30, 2023 · CBAY Signals & Forecast. Mostly positive signals in the chart today. The Cymabay Therapeutics Inc stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. What happened. Shares of CymaBay Therapeutics ( CBAY -1.16%) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced ...CBAY is a biotechnology company that develops treatments for neurological disorders. The stock price forecast shows a strong buy signal from the 3-month …According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts

CBM Bancorp, Inc. (CBMB) share price prediction for 2023, 2024, 2025, 2026 and 2027. CBMB one year forecast. CBM Bancorp stock monthly and weekly forecasts.

Find the latest CymaBay Therapeutics, Inc. (CBAY) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

NextPlay Technologies, Inc. (NASDAQ:NXTP) announced its quarterly earnings results on Wednesday, January, 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The firm earned $4.20 million during the quarter, compared to the consensus estimate of $5.70 …Stock Price Forecast. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of 22.00, with a high estimate of 33.00 and a low estimate of 19.00. The median estimate represents a +76.85% increase from the last price of 12.44.The stock is selling for $9.87 and its $13.89 average price target suggests a 12-month upside potential of ~41%. (See CBAY stock forecast ) Cerevel Therapeutics ( CERE )At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ... The above table shows the analyst CBAY forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$18.03Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...For CymaBay Therapeutics stock forecast for 2023, 1 predictions are offered for each month of 2023 with average CymaBay Therapeutics stock forecast of $19.97, a high forecast of $19.97, and a low forecast of $19.97. The average CymaBay Therapeutics stock forecast 2023 represents a 4.58% increase from the last price of $19.1000003814697.He kept his outperform rating on CBAY stock and raised his price target to 20 from 18. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This ...CymaBay Therapeutics Stock Forecast and Price Target. If CymaBay Therapeutics's stock price reached the average yearlong target of $10.00 given by five well-known analysts in recent months, there would be a potential downside of approximately -18.57% from its last closing price in July, 2023.há 4 dias ... Cymabay Therapeutics Inc (NASDAQ:CBAY) shares, rose in value on Thursday, November 30, with the stock price up by 3.99% to the previous ...Dec 1, 2023 · CBAY Earnings Date and Information. CymaBay Therapeutics last posted its earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02.

Find the latest Cidara Therapeutics, Inc. (CDTX) stock quote, history, news and other vital information to help you with your stock trading and investing.CymaBay Therapeutics Inc (CBAY) stock is trading at $11.76 as of 11:26 AM on Monday, Jul 3, a rise of $0.81, or 7.39% from the previous closing price of $10.95. The stock has traded between $10.95 and $11.77 so far today. Volume today is low. So far 1,522,720 shares have traded compared to average volume of 2,310,531 shares.NextPlay Technologies, Inc. (NASDAQ:NXTP) announced its quarterly earnings results on Wednesday, January, 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The firm earned $4.20 million during the quarter, compared to the consensus estimate of $5.70 …Traders may consider buying the stock or exploring call options. I backtested 91 similar cases where CBAY's Momentum Indicator exceeded 0, and 78 of them led t This indicator may be signaling that CBAY's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or ... Instagram:https://instagram. reviews of humana medicare advantage plansev problemsschwab low cost index fundsstock options newsletters That closing price of FOSL’s stock is at a discount of -300.0% from its 52-week high price of $6.08 and is indicating a discount of -3.29% from its 52-week low price of $1.57. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.37 million shares which gives us an average trading volume of 360.25K if we … top international etfsstz shares CDTX Stock 12 Months Forecast. Based on 1 Wall Street analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 679.22% change from the last price of $0.77.Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Verastem Inc have a median target of 32.00, with a high estimate of 36.00 and a low estimate of 17.50. The median ... economic collapse china 1,785.90 +6.50(+0.37%) Crude Oil (+0.21%) Advertisement CymaBay Therapeutics, Inc. (CBAY) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M …Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts